CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-399

Microbiology Review(s)

Product Quality Microbiology Review
Review for HFD-150

26 September 2002

NDA: 21-399

Drug Product Name
Proprietary: Iressa® Tablets
Non-proprietary: gefitnib
Drug Product Classification: Oral Dosage Form

Review Number: 1

Subject of this Review
Submission Date: 01 August 2002
Receipt Date: 02 August 2002
Consult Date: 17 September 2002
Date Assigned for Review: 26 September 2002

Applicant/Sponsor
Name: AstraZeneca Pharmaceuticals
Address: 1800 Concord Pike, P.O. Box 8355, Wilmington, DE 19803-8355
Representative: Ronald C. Falcone
Telephone: (302)886-2715

Name of Reviewer: Paul Stinavage

Conclusion: The application is recommended for approval on the basis of microbiological quality of the drug product.

Product Quality Microbiology Data Sheet

A. 1. **TYPE OF SUPPLEMENT:** N/A

2. **SUPPLEMENT PROVIDES FOR:** N/A

3. **MANUFACTURING SITES:** Macclesfield, Cheshire, Suffolk, UK

4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Tablet

5. **METHOD(S) OF STERILIZATION:** N/A

6. **PHARMACOLOGICAL CATEGORY:** The product is an antineoplastic.

B. **SUPPORTING/RELATED DOCUMENTS:**

C. **REMARKS:** The product is a non-sterile dosage form.

filename: n21399.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability – The application is recommended for approval on the basis of microbiological quality of the drug product.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable -

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – N/A

B. Brief Description of Microbiology Deficiencies – none

III. Administrative

A. Reviewer's Signature _____

B. Endorsement Block
P. Stinavage
P.H. Cooney

C. CC Block
cc:
Original NDA 21-399
HFD-150/Division File/NDA 21-399/R. Lostritto/A. Baird

Product Quality Microbiology Assessment

The product does not have a microbiological limits specification. In the case of a dry tablet this is appropriate. As is evident from microbiological tests performed as a portion of the stability protocol there is limited microbiological contamination of the drug product. In addition, because this is a dry tablet there is very little opportunity for microbiological proliferation during storage of the drug product.

Up to [redacted] CFU/gram yeast and mold were detected in the drug product following long term storage (in excess of [redacted] month storage). No microbiological contamination was detected prior to or at the [redacted] month time point. The contamination rate of [redacted] CFU/gram would represent approximately [redacted] CFU/250 mg tablet. Even this level of contamination in a dry, oral dosage form does not present significant microbiological risk.

Satisfactory

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Paul Stinavage
9/26/02 11:16:59 AM
MICROBIOLOGIST
Tablet for non-small cell lung carcinoma.

Peter Cooney
9/26/02 03:41:37 PM
MICROBIOLOGIST